Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The JointJYNT -1.22%63 EV-to-EBIT is 161.79 as of Jul. 18, 2026, which is 121% above its 10-year median of 73.18. GuruFocus rates JYNT with a GF Score™ of 63/100 and a GF Value™ of $11.20 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 470 Healthcare Providers & Services companies, The Joint ranks worse than 95.74% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
The Joint's Enterprise Value for the quarter that ended in Mar. 2026 was $107.65 Mil.
The Joint's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Joint EV-to-EBIT Related Terms
The Joint EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for The Joint's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Joint's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where The Joint's EV-to-EBIT falls into.
The Joint's current Enterprise Value is $108.40 Mil.
The Joint's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Joint (JYNT) has a EV-to-EBIT of 161.79 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on The Joint and its competitors. This is 121% above median its historical median of 73.18. According to the industry distribution chart, The Joint ranks #450 out of 470 companies in the Healthcare Providers & Services industry, placing it in the top 95.7%.
Is The Joint's EV-to-EBIT too high?
The Joint's current EV-to-EBIT of 161.79 is 121% above median its 10-year median of 73.18. The Healthcare Providers & Services industry median EV-to-EBIT is 15.72. The Joint's value of 161.79 is 929.2% above this industry median. Based on the distribution chart, The Joint ranks #450 out of 470 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Joint has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's EV-to-EBIT compare to PARK and WW?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #450 out of 470 companies for EV-to-EBIT. This places The Joint in the lower half of its industry. The industry median EV-to-EBIT is 15.72. The Joint's value of 161.79 is 929.2% above this benchmark. While the company's 10-year median is 73.18 vs. the industry median of 15.72, The Joint has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.72, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Joint's current EV-to-EBIT of 161.79 is 929.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on The Joint and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current EV-to-EBIT is 161.79, which is 121% above median its own 10-year median of 73.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.20, compared to a current price of $8.92 — trading 20.4% below its estimated fair value. The current EV-to-EBIT is 161.79, which is 121% above median its 10-year median of 73.18 and 929.2% above the Healthcare Providers & Services industry median of 15.72. The Joint's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For The Joint (JYNT), the current EV-to-EBIT is 161.79 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.92 is trading 20.4% below its estimated GF Value™ of $11.20.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
EV-to-EBIT: 161.79 (121% above median its 10-year median of 73.18)
GF Value™: $11.20 vs. price of $8.92 (20.4% below fair value)
Industry Position: 929.2% above the Healthcare Providers & Services median (#450 of 470)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
63GF Score
Get the complete analysis for JYNT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
